Studies

Oesofaguscarcinoom, fase III, operabel HER2-positief

dMMR oesofagogastrisch carcinoom, fase II, HER2-negatief, MSI-positief

T4N0 / stadium III resectabel coloncarcinoom, MSI-H; perioperatief dostarlimab versus SOC

UCC, fase II, cT4NxM0 of cTxN1-N3M0, neo-adjuvant avelumab na neo-adjuvante chemotherapie

Ovariumcarcinoom, fase I, 2e lijn, selectieve WEE1 remmer (+carboplatine)

Solide tumoren, fase I, MET, MET kinase inhibitor

Solide tumoren, EMA geregistreerde middelen

Solide tumoren, ‘actionable’ moleculaire target

Salivary duct carcinoom, fase II, dutasteride en CAB 

Ovariumcarcinoom, fase II, BRCAwt, UV1-olaparib-durvalumab

NMIBC niet responsief op BCG, fase 1, intravesicaal eciskafusp i.c.m. BCG

Recidief glioblastoom, genoomanalyse

Adenocarcinoom slokdarm maag, fase II, HER2-, F-doublets (F-Nal-IRI, CapCar and CapOx)

mCRC, fase I/II, petosemtamab + folfiri

Neuro-endocrien prostaatcarcinoom, fase Ib/II, immuuntherapie

mCRPC, fase III, MK-5684 + HRT vs abiraterone / enzalutamide 

mHSPC, fase III, ADT +/- duralotamide 

Rectumcarcinoom, fase III, clear resection margin (R0 resection)

mCRPC, moleculaire screening

mCRPC, fase I, Lu-PSMA-617

Sarcomen, fase I, radiotherapie, DDR remmers

Ovariumcarcinoom, peritoneale kanker, fase I/II, hoog CA-125, cemiplimab and MUC16-antibody

CROSS neoadjuvante chemoradiotherapie, fase II, actieve surveillance, nivolumab

NRAS gemuteerd melanoom, fase III, naporafenib + trametinib vs 'physician's choice'

Epitheliaal ovariumcarcinoom, fase I/II, dendritische cel vaccinatie (XP-DC)

DDLPS of LMS, fase III, neoadjuvante chemotherapie

UCC, fase II, cT2-4aN0 or cT1-4aN1, pre-operatieve nivolumab + relatlimab